Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Cheng, Ann-Lii, Qin, Shukui, Ikeda, Masafumi · Journal of Hepatology · 2022